Program 01 Breast Cancer

计划 01 乳腺癌

基本信息

批准号：
10540358
负责人：
ERIC P WINER
金额：
$ 4.29万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-03-10 至 2026-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10540358
关键词：
Acceleration Address African American population Age Antibody-drug conjugates Artificial Intelligence BRCA1 gene Basic Science Biological Biology Brain Breast Cancer Patient Breast cancer metastasis Cancer Center Cancer Center Support Grant Caring Catchment Area Cells Characteristics Clinic Clinical Clinical Trials Collaborations Collection Cytotoxic T-Lymphocytes Dana-Farber Cancer Institute Data Detection Diagnosis Direct Costs Disease Disparity ERBB2 gene Early Diagnosis Ensure FDA approved Fertility Funding Genomics Goals Heterogeneity Immunologics Immunotherapeutic agent Immunotherapy Individual Infrastructure Institution Knowledge Laboratories Late Effects Lesion Local Therapy Malignant Neoplasms Massachusetts Metastatic malignant neoplasm to brain Mission Morbidity - disease rate Mutation Nature Oncology Paclitaxel Paper Pathogenesis Patient Outcomes Assessments Patients Peer Review Grants Pre-Clinical Model Prevention Prognosis Publishing Race Regimen Research Research Personnel Resistance Resource Sharing Socioeconomic Status Strategic Planning Systemic Therapy T cell response Toxic effect Translational Research Translations Trastuzumab Tumor Biology Work age related cancer care cancer cell cohort improved improved outcome innovation inter-institutional investigator-initiated trial malignant breast neoplasm member mortality mouse model novel strategies patient derived xenograft model phase II trial preclinical study programmed cell death ligand 1 programs racial disparity screening survivorship targeted treatment translational study trial comparing triple-negative invasive breast carcinoma tumor tumor microenvironment young woman

项目摘要

Breast Cancer Program Project Summary / Abstract The mission of the Breast Cancer Program is to reduce morbidity and mortality from breast cancer through innovative basic and translational research and the conduct of impactful clinical trials. The Program’s members work collaboratively to advance knowledge across the continuum of breast cancer: from prevention, screening, and early diagnosis to treatment and survivorship. The goals are to increase cure rates and reduce morbidity among those who ultimately succumb to the disease and those who live with the late effects of therapy. The program has 117 members (73 primary and 44 secondary), representing all seven DF/HCC institutions and 16 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $8.1 million in direct costs from the NCI and $2.4 million from other sponsors. During the current funding period, primary Program members published 936 cancer-relevant papers. Of these, 28% were inter-institutional, 22% were intra-programmatic, and 42% were inter-programmatic collaborations between two or more DF/HCC members. To achieve the Program’s mission, our Specific Aims are to 1) Define and address the heterogeneity in triple-negative breast cancer; 2) Characterize the biology to improve outcomes from breast cancer metastases to the brain; 3) Improve the efficacy of immunotherapy for breast cancer; 4) Improve personalized local-regional therapy; and 5) Ensure that Program advances serve Massachusetts and the nation by addressing racial disparities and access to cancer care. These Aims align closely with the DF/HCC Strategic Plan and will be achieved through the established and invaluable CCSG infrastructure for collaborative transdisciplinary research, Shared Resources, and a unified clinical trials apparatus that accelerates translation of the Program’s laboratory discoveries to the clinic.

乳腺癌计划项目摘要 /摘要乳腺癌计划的任务是通过通过创新的基础和翻译研究以及有影响力的临床试验的进行。该计划的成员共同努力促进跨乳腺癌连续性的知识：预防，筛查，以及治疗和生存的早期诊断。目标是提高治愈率并降低发病率在最终屈服于该疾病的人中，以及那些患有治疗后期作用的人。该计划有117名成员（73名主要和44个中学），代表所有七个DF/HCC机构和16个学术部门。 2019年，该计划归因于同行评审的赠款为810万美元 NCI的直接成本和其他赞助商的240万美元。在当前的资金期间，主要计划成员发表了936份与癌症有关的论文。其中28％是机构间，22％是在两个或多个DF/HCC成员之间进行了程序内的合格次数介绍。为了实现该计划的使命，我们的具体目的是1）定义和解决异质性三阴性乳腺癌； 2）表征生物学以改善乳腺癌的预后转移到大脑； 3）提高免疫疗法对乳腺癌的效率； 4）改进个性化地方区域疗法； 5）确保计划的进步服务于马萨诸塞州和通过解决种族分布和获得癌症护理的机会来解决国家。这些目的与DF/HCC战略计划紧密相符，将通过已建立和可用于协作跨学科研究，共享资源的宝贵CCSG基础架构和统一临床试验设备加速了该计划的实验室发现向诊所的翻译。